National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Menopausal Hormone Replacement Therapy (HRT)
    Posted: 07/09/2002    Updated: 10/03/2006



Links to NCI Materials






Links to Other Materials






Current Clinical Trials



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Related Pages
Breast Cancer Home Page
NCI's gateway for information about breast cancer.

Colon and Rectal Cancer Home Page
NCI's gateway for information about colon and rectal cancer.

Ovarian Cancer Home Page
NCI's gateway for information about ovarian cancer.
Links to NCI Materials

Menopausal hormone use (sometimes referred to as hormone replacement therapy or HRT) usually involves treatment with either estrogen alone or a combination of estrogen with progesterone or progestin, a synthetic hormone with effects similar to those of progesterone.

The best evidence for the risks and benefits of menopausal hormone replacement therapy comes from the Women's Health Initiative (WHI), a large randomized clinical trial including more than 16,000 healthy women, sponsored by the National Institutes of Health (NIH).

Results from the trial published in 2002 showed that the overall risks of estrogen plus progestin outweigh the benefits. Among the risks observed after 5.6 years of follow-up were increased risks of breast cancer, heart disease, stroke and blood clots.

On March 1, 2004, after nearly seven years of follow-up, NIH stopped the estrogen-alone arm of the trial, concluding that estrogen alone does not appear to affect (either increase or decrease) heart disease, a key question of the study. In addition, estrogen alone appears to increase the risk of stroke and decrease the risk of hip fracture. No increase in breast cancer risk was observed during the study period.

Menopausal Hormone Replacement Therapy Use and Cancer: Questions and Answers
(Reviewed: 10/05/2007) - A fact sheet about the results of research on menopausal hormone replacement therapy use. Includes information about the effect of menopausal hormone replacement therapy use on the body. Also outlines the benefits and risks of using menopausal hormones. National Cancer Institute Fact Sheet 3.76

Menopausal Hormone Therapy and Ovarian Cancer: Questions and Answers
(Posted: 10/03/2006) - In a recent study published in the Journal of the National Cancer Institute, NCI and AARP reported that five or more years of estrogen plus progestin use significantly increased the risk of ovarian cancer for women who have not had a hysterectomy.

Hormone Replacement Therapy and Breast Cancer Relapse
(Posted: 02/05/2004, Reviewed: 04/08/2008) - Breast cancer survivors who took hormone replacement therapy (HRT) to relieve menopausal symptoms had more than three times as many breast cancer recurrences as survivors who did not take HRT, according to a Lancet report published online February 3, 2004.

Increased Risk of Ovarian Cancer Is Linked to Estrogen Replacement Therapy
(Posted: 07/16/2002) - Researchers from the NCI have found that women in a large study who used estrogen replacement therapy after menopause were at increased risk for ovarian cancer.

Experts Weigh in on Hormone Therapy
(Posted: 08/30/2002) - The stopping of a major hormone therapy trial in early July 2002 has sent many women to their health care providers for advice on whether to continue hormone use.

Uso de hormonas después de la menopausia: preguntas y respuestas
(Publicación: 07/09/2002) - La menopausia es la transición entre los años en los que una mujer puede embarazarse y los años en los que el embarazo ya no es posible.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov